Additional Treatment for Isolated Local Pancreatic Cancer Recurrence Using Stereotactic Body Radiation Therapy

Patient reported Quality of Life as assessed using Exocrine Pancreatic Insufficiency (EPI) questionnaire

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported non-disease specific health-related Quality of Life (HRQoL) as assessed using the EQ-5D-5L

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported cancer-specific HRQoL as assessed using the EORTC QLQ-C30

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported tumor-specific HRQoL as assessed using the EORTC LQPAN26

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported chemotherapy-induced peripheral neuropathy as assessed using the EORTC QLQ-CIPN20

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported Quality of Life as assessed using the happiness, hospital, anxiety and depression scale (HADS)

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Patient reported Quality of Life as assessed using the worry of progression of cancer scale (WOPS)

Part of the Patient Reported Outcome Measures (PROMs) that are being standardly measured in PACAP-participants.

Time frame: At baseline and at 3, 6, 9, 12, 18 and 24 months and every subsequent year after enrollment in the PACAP-cohort. Assessed through study completion, up to 18 months

Treatment response assessed on CT-imaging (graded according to RECIST guidelines)

Response to SBRT treatment.

Time frame: During and immediately after the intervention (SBRT treatment)

Acute and late toxicity of SBRT as assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Assessed during regular follow-up moments. In the intervention arm acute toxicity will be monitored by the treating radiation oncologist. Acute toxicity will be defined as toxicity within 90 days from the end of SBRT treatment and will be assessed in week 1, 3, 6 and 12. Late toxicity is defined as toxicity occurring \> 90 days from SBRT.

Time frame: Through study completion, an average of 18 months

Overall survival

The interval between the date of primary resection and the date of death from any cause or last follow-up.

Time frame: From the date of primary resection until the date of death from any cause or last follow-up, whichever came first, assessed up to 18 months

Progression-free survival

The interval between the date of disease recurrence and the date that local and/or distant progression of disease occurs.

Time frame: From the date of disease recurrence until the date that local and/or distant progression of disease occurs, assessed up to 18 months

Local progression-free survival

The interval between the date of disease recurrence and the date that locoregional progression of disease occurs.

Time frame: From the date of disease recurrence until the date that locoregional progression of disease occurs, assessed up to 18 months

Distant metastases free survival

The interval between the date of disease recurrence and the date that distant progression of disease occurs.

Time frame: From the date of disease recurrence until the date that distant progression of disease occurs, assessed up to 18 months

Reasons for non-eligibility or exclusion for SBRT treatment

e.g. poor condition, patients wish, deteriorated condition, age.

Time frame: At the time the patient is assessed eligible for the intervention. Assessed through the study, up to 18 months